• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利福昔明对肠易激综合征结局的有效性：随机对照试验的系统评价和荟萃分析

Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

作者信息

Khan Zarghuna, Khan Saad Khalid, Reyaz Ibrahim, Anam Hemalatha, Ijaz Osama, Attique Ilqa, Shahzad Zoha, Saleem Faraz

机构信息

Internal Medicine, Rehman Medical Institute, Peshawar, PAK.

Medicine, Army Medical College, Rawalpindi, PAK.

出版信息

Cureus. 2023 Sep 6;15(9):e44807. doi: 10.7759/cureus.44807. eCollection 2023 Sep.

DOI:10.7759/cureus.44807
PMID:37809182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10558962/
Abstract

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder that impacts the lives of many individuals worldwide. We conducted a systemic review and meta-analysis of randomized controlled trials (RCTs) to assess both the effectiveness of rifaximin in alleviating IBS symptoms and its potential adverse effects. PubMed, Web of Science, Embase, the Cochrane Library, Scopus, and Google Scholar were searched from inception until August 20, 2023, for studies comparing rifaximin with placebo in the resolution of symptoms among IBS patients. Risk ratios (RRs) and their corresponding 95% confidence intervals (CIs) were derived for all the outcomes of interest. Six RCTs were pooled in this analysis. The results showed improved abdominal distension with rifaximin over the control group. Overall symptom relief at the end of the treatment period and follow-up period was also observed in the patients receiving rifaximin. However, no significant differences were found between the rifaximin group and the control group for the outcomes of abdominal pain, nausea, headache, vomiting, diarrhea, sinusitis, bronchitis, and upper respiratory tract infection. The results of our meta-analysis support the use of rifaximin in the treatment of IBS, owing to its safety and effectiveness. Future RCTs should be conducted to assess this topic of interest more extensively.

摘要

肠易激综合征（IBS）是一种常见的胃肠道疾病，影响着全球许多人的生活。我们对随机对照试验（RCT）进行了系统评价和荟萃分析，以评估利福昔明缓解IBS症状的有效性及其潜在的不良反应。检索了PubMed、科学网、Embase、考克兰图书馆、Scopus和谷歌学术，从建库至2023年8月20日，查找比较利福昔明与安慰剂对IBS患者症状缓解情况的研究。对所有感兴趣的结局得出风险比（RR）及其相应的95%置信区间（CI）。本分析纳入了6项RCT。结果显示，与对照组相比，利福昔明组的腹胀情况有所改善。接受利福昔明治疗的患者在治疗期结束和随访期时总体症状也有所缓解。然而，在腹痛、恶心、头痛、呕吐、腹泻、鼻窦炎、支气管炎和上呼吸道感染等结局方面，利福昔明组与对照组之间未发现显著差异。我们的荟萃分析结果支持使用利福昔明治疗IBS，因其安全性和有效性。未来应开展RCT以更广泛地评估这一感兴趣的主题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/ff365cc03040/cureus-0015-00000044807-i14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/b2b769550438/cureus-0015-00000044807-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/92e2277e239b/cureus-0015-00000044807-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/8eaf82edb838/cureus-0015-00000044807-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/7f7f3f4b62d8/cureus-0015-00000044807-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/3c8ed6f43ccf/cureus-0015-00000044807-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/569b5fa15e3b/cureus-0015-00000044807-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/8690644d07a4/cureus-0015-00000044807-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/8f58ccc10b0f/cureus-0015-00000044807-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/c66a4e70a8be/cureus-0015-00000044807-i09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/2fb08076e155/cureus-0015-00000044807-i10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/34723e938e1e/cureus-0015-00000044807-i11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/dcec8cf5ba7a/cureus-0015-00000044807-i12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/96117a152349/cureus-0015-00000044807-i13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/ff365cc03040/cureus-0015-00000044807-i14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/b2b769550438/cureus-0015-00000044807-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/92e2277e239b/cureus-0015-00000044807-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/8eaf82edb838/cureus-0015-00000044807-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/7f7f3f4b62d8/cureus-0015-00000044807-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/3c8ed6f43ccf/cureus-0015-00000044807-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/569b5fa15e3b/cureus-0015-00000044807-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/8690644d07a4/cureus-0015-00000044807-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/8f58ccc10b0f/cureus-0015-00000044807-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/c66a4e70a8be/cureus-0015-00000044807-i09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/2fb08076e155/cureus-0015-00000044807-i10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/34723e938e1e/cureus-0015-00000044807-i11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/dcec8cf5ba7a/cureus-0015-00000044807-i12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/96117a152349/cureus-0015-00000044807-i13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4de/10558962/ff365cc03040/cureus-0015-00000044807-i14.jpg

相似文献

1
Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.利福昔明对肠易激综合征结局的有效性：随机对照试验的系统评价和荟萃分析
Cureus. 2023 Sep 6;15(9):e44807. doi: 10.7759/cureus.44807. eCollection 2023 Sep.
2
Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials.利福昔明治疗肠易激综合征：随机安慰剂对照试验的荟萃分析
Medicine (Baltimore). 2016 Jan;95(4):e2534. doi: 10.1097/MD.0000000000002534.
3
The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.利福昔明治疗肠易激综合征的疗效和安全性：系统评价和荟萃分析。
Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Rifaximin: new therapeutic indication and future directions.利福昔明：新的治疗适应证和未来方向。
Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Epub 2011 Jul 7.
6
Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis.治疗便秘型或腹泻型肠易激综合征的已获许可药物试验中的不良事件：系统评价与荟萃分析。
Neurogastroenterol Motil. 2022 Jun;34(6):e14279. doi: 10.1111/nmo.14279. Epub 2021 Oct 20.
7
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.腹泻型肠易激综合征管理的最新进展：聚焦利福昔明和埃索美拉嗪。 （注：原文中Eluxadoline应为Eluxadroline，中文通用名是埃索美拉嗪，是一种治疗腹泻型肠易激综合征的药物。这里按照正确名称翻译了，原译文可能存在拼写错误。）
Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11.
8
Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.利福昔明治疗腹泻型肠易激综合征的单个及多个症状：使用新终点的分析。
Clin Ther. 2023 Mar;45(3):198-209. doi: 10.1016/j.clinthera.2023.01.010. Epub 2023 Mar 14.
9
Different therapies of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome: A network meta-analysis of double-blinded, placebo-controlled trials.中药治疗腹泻型肠易激综合征的不同疗法：一项双盲、安慰剂对照试验的网络荟萃分析。
J Ethnopharmacol. 2023 Dec 5;317:116672. doi: 10.1016/j.jep.2023.116672. Epub 2023 Jun 14.
10
Physical activity for treatment of irritable bowel syndrome.体力活动治疗肠易激综合征。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD011497. doi: 10.1002/14651858.CD011497.pub2.

引用本文的文献

1
Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives.用于肠-脑互动障碍的粪便微生物群移植：当前见解、有效性及未来展望
Curr Gastroenterol Rep. 2025 Jul 9;27(1):50. doi: 10.1007/s11894-025-01001-6.

本文引用的文献

1
Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies.5-羟色胺3受体拮抗剂治疗肠易激综合征的比较疗效：随机对照研究的网状Meta分析
Ann Gastroenterol. 2021 Jul-Aug;34(4):535-546. doi: 10.20524/aog.2021.0619. Epub 2021 Apr 2.
2
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.《PRISMA 2020声明：报告系统评价的更新指南》
Syst Rev. 2021 Mar 29;10(1):89. doi: 10.1186/s13643-021-01626-4.
3
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.
根据罗马 III 或 IV 标准，全球肠易激综合征的患病率：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20.
4
Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review.心理干预对改善 1 型和 2 型糖尿病自我管理的效果：系统综述。
Health Technol Assess. 2020 Jun;24(28):1-232. doi: 10.3310/hta24280.
5
Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.腹泻型肠易激综合征患者对利福昔明的腹痛反应
Clin Transl Gastroenterol. 2020 Mar;11(3):e00144. doi: 10.14309/ctg.0000000000000144.
6
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.药物治疗对腹泻型肠易激综合征或混合型肠易激综合征患者的疗效：系统评价和网络荟萃分析。
Gut. 2020 Jan;69(1):74-82. doi: 10.1136/gutjnl-2018-318160. Epub 2019 Apr 17.
7
Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome.系统评价与荟萃分析：益生元、益生菌、合生菌和抗生素治疗肠易激综合征的疗效。
Aliment Pharmacol Ther. 2018 Nov;48(10):1044-1060. doi: 10.1111/apt.15001. Epub 2018 Oct 8.
8
Pathophysiology of irritable bowel syndrome.肠易激综合征的病理生理学。
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):133-146. doi: 10.1016/S2468-1253(16)30023-1. Epub 2016 Sep 8.
9
Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.腹泻型肠易激综合征患者的健康相关生活质量、工作效率及间接成本
Health Qual Life Outcomes. 2017 Feb 14;15(1):35. doi: 10.1186/s12955-017-0611-2.
10
Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.利福昔明重复治疗对腹泻型肠易激综合征患者安全有效。
Gastroenterology. 2016 Dec;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003. Epub 2016 Aug 13.